

Press Release

For Immediate Release

Granules India appoints Dr. K.V.S Ram Rao as Joint Managing Director and Chief Executive Officer

Hyderabad, 4th January, 2022: Granules India Limited (GIL), a vertically integrated pharmaceutical company, today announced the appointment of Dr. K.V.S Ram Rao as Joint Managing Director & Chief Executive Officer (CEO) with effect from January 05, 2022. Dr Ram Rao has over two decades of experience in pharmaceutical and chemical industries.

Dr. Ram Rao holds a bachelor's degree in chemical engineering from Osmania University, Hyderabad and a master's degree & Ph.D. in chemical engineering from Indian Institute of Science, Bangalore. He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management. He worked as Executive Director & CEO for CSM Business of PI Industries Limited. He played a significant role in Dr. Reddy's Laboratories Limited while working in various capacities from 2000 to 2018. He also worked with Jubilant Life Sciences and Gujarat Heavy Chemicals Ltd.

Commenting on the appointment, **Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of GIL** said, *"I am excited to welcome Dr. K.V.S Ram Rao to Granules as Joint Managing Director and CEO. During the past few years, we have stressed the importance of building a company around the pillars of efficiencies and sustainability. Dr. Ram Rao's varied experience in the areas of Chemical and API businesses including R&D and Manufacturing through adoption of innovative technology and best practices in sustainability, will further strengthen Granules' drive towards becoming a strong integrated manufacturer with unparalleled efficiencies."*

Dr. Rao is well known for leadership capability in making high stake decisions and overcoming complex business challenges and is expert at articulating and implementing change while gaining consensus from people with differing agenda. He established innovative business models with eminent team dynamics and instituted good manufacturing and R&D systems. He also built best in class practices in environment, health & safety and nurtured excellent diversity & inclusivity policies. He has strong market knowledge, financial/analytical skills, customer-oriented approach, industry network at multiple levels, well-grounded principles of governance & ethics.

END

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best in class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Safe Harbor: This document is to provide the general background information about the Company's activities as at the date of the release. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Investor Contacts:**Krishna Raghunathan**

Vice President – Finance and Investor Relations

040-69043573

krishna.raghunathan@granulesindia.com**Chaitanya Tummala**

Company Secretary

040-69043614

chaitanya.tummala@granulesindia.com